The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.

For those ultimately able to fill the prescription, study revealed treatment was delayed by 12 days on average.

Mean total annual payment increased from $4936 to $6722 and from $2651 to $6811 for those with and without diabetes, respectively.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.

HT2A receptor inverse agonist advances in clinical development, with phase 2 trial results anticipated in late 2026.

Most obesity drugs do not improve quality of life or heart health, according to a review published online July 8 in The BMJ.

Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

The transition from accelerated to traditional approval is backed by robust 24-month eGFR data from the phase 3 APPLAUSE-IgAN trial.

Following a manufacturing-related Complete Response Letter in June 2026, the resubmitted application for the once-monthly subcutaneous depot is back under FDA review.